Understanding potential risks early and advancing the right compounds can be a difficult task. Many early safety assays can be overly sensitive and lack specificity, potentially limiting development pipelines and increasing costs in drug development. To better predict potential risks and reduce unwarranted drug discovery attrition, a greater emphasis needs to be placed on the accurate evaluation of potential risks earlier in development.
Check out our poster presentations from the Society of Toxicology's 2018 annual meeting.
Charles River offers in vitro preclinical cardiac risk assessment services which are strengthened by industry-leading safety pharmacology expertise. A comprehensive survey of non-GLP assays, including cardiac ion channels and cardiomyocyte assays, provide insight into potential cardiac risk and aid in effective decision-making in early preclinical development. GLP offerings, including hERG and action potential duration (ADP) assays, are recommended candidate selection and IND submissions. Our integrated in vitro and in vivo scientists can interpret your results and design in vivo assays to advance your program further.